BKV CEO sells 200,000 shares under 10b5-1 at $26.16, $27.13

BKV Corp insider activity: the Chief Executive Officer and Director reported open‑market sales of company stock under a Rule 10b5‑1 trading plan adopted on March 14, 2025.

Rhea-AI Filing Summary

BKV Corp insider activity: the Chief Executive Officer and Director reported open‑market sales of company stock under a Rule 10b5‑1 trading plan adopted on March 14, 2025.

The insider sold 100,000 shares on 11/10/2025 at a weighted average price of $26.1586 and 100,000 shares on 11/11/2025 at a weighted average price of $27.1314. Following the transactions, directly held shares were 1,348,580. An additional 875,754 shares are reported as indirectly owned by spouse.

Insider Trade Summary

Net Seller: 200,000 shares

Net Sell 3 txns

Insider Kalnin Christopher P

Role Chief Executive Officer

Sold 200,000 shs ($5.33M)

Type	Security	Shares	Price	Value
Sale	Common Stock	100,000	$27.1314	$2.71M
Sale	Common Stock	100,000	$26.1586	$2.62M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,348,580 shares (Direct); Common Stock — 875,754 shares (Indirect, By Spouse)

Footnotes (3)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025.
2. F2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.565, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BKV (BKV) disclose in this Form 4?

The CEO and Director reported selling 100,000 shares on 11/10/2025 at $26.1586 and 100,000 shares on 11/11/2025 at $27.1314.

Was the BKV insider sale under a 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5‑1 trading plan adopted on March 14, 2025.

How many BKV shares does the insider hold after these sales?

Direct beneficial ownership is 1,348,580 shares after the reported transactions.

Are there any indirectly owned BKV shares reported?

Yes. The filing lists 875,754 shares as indirectly owned by spouse.

What price ranges were the BKV shares sold at?

Per footnotes, sales were executed in multiple trades ranging from $26.00–$26.43 on 11/10/2025 and $27.00–$27.565 on 11/11/2025.

What roles does the reporting person hold at BKV?

The reporting person is a Director and serves as Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 11:44 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalnin Christopher P

(Last) (First) (Middle)

1200 17TH STREET, SUITE 2100

(Street)

DENVER CO 80202

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BKV Corp [ BKV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		S(1)		100,000	D	$26.1586(2)	1,448,580	D
Common Stock	11/11/2025		S(1)		100,000	D	$27.1314(3)	1,348,580	D
Common Stock								875,754	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.565, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Kathleen Lenox, attorney-in-fact	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.